AtonRa Partners reduced its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 21.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,875 shares of the company’s stock after selling 3,753 shares during the period. AtonRa Partners’ holdings in […]